Cancer Diagnosis and Therapy Congress | 3 – 4 September 2015 | London – UK

Cancer is one of the leading causes of deaths world over with 14 million new cases in 2012. This number is expected to reach 22 million within the next two decades.

Download event brochure for more information

In the next year or two, doctors will begin routinely monitoring cancer using a potentially revolutionary technique that searches for a genetic signature in a blood sample, according to experts in the field. The new method, known as a “liquid biopsy,” holds the promise of detecting the reappearance of cancer much earlier and more accurately than current methods. And in years to come, this method could also provide a better, less invasive way to diagnose disease than a tissue biopsy. - Gulf Times

MarketsandMarkets Conferences in an initiative to bring global cancer experts under one roof will be organizing a congress in London – UK known as the Cancer Diagnosis and Therapy Congress. The congress will be held on 3 – 4 September 2015.

The congress through its streams and blend of speakers will aim to cover a wide range of topics. It will look at advanced cancer detection, diagnosis methods and technologies, novel approaches to cancer therapy and emerging challenges in organ specific cancers research.

Cancer Diagnosis

  • Interventional Oncological Therapies in the Treatment of Liver Metastases by Prof. Thomas J. Vogl - Director, Department of Diagnostic & Interventional Radiology, Wolfgang Goethe-University, Germany
  • Electrochemical Biosensors for Prostate Cancer Diagnosis by Dr. Pedro Estrela - Associate Professor, Department of Electronic & Electrical Engineering, University of Bath, UK
  • The merits/Demerits Between Artificial and Instruments to Diagnosis in Ancient Medicine and Modern Medicine by Prof. Feng-Chi Ho - President, Global Oncology Academy Guangzhou East Cancer Hospital, China.

Cancer Therapy

  • NGS and Bioinformatics for Cancer Immunotherapies by Dr. John Castle - Senior Director, Bioinformatics, Agenus & 4-Antibody AG, Basel, Switzerland
  • Molecular Targeted Therapeutics: Focus on Drug Resistance by Prof. Hani Gabra - Professor of Medical Oncology, Imperial College London, UK; Director, Ovarian Cancer Action Research Centre
  • Hypoxic Micro-Environments may be the Primary Driver of Uncontrollable Tumor Growth by William P. Chastain - Director & Founder, APeX Disease Reserch Institute, USA
  • Lung Cancer Treatment Using Immune System Wins F.D.A. Approval

The first immune-based treatment for lung cancer won approval from the Food and Drug Administration on Wednesday, and it could displace more conventional chemotherapy for certain patients, at least. The drug, Opdivo, from Bristol-Myers Squibb, is one of a class of medicines that have electrified oncologists in recent years because they free the body’s own immune system to attack tumors. - NY Times

Other Industry Events

Speaker representation from

  • GlaxoSmithKline
  • University of Oxford
  • Cambridge Biomedical Centre
  • UCL Cancer Institute
  • Cancer Research UK
  • Cellzome

Media Contact:

Ajay Nimbalkar

Assistant Manager | Web Marketing
MarketsandMarkets Conferences